Oramed Pharmaceuticals Inc
WKN: A1CTNU / ISIN: US68403P2039Oramed Pharmaceuticals Inc.
| eröffnet am: | 28.03.07 13:46 von: | OttomanRosendahl |
| neuester Beitrag: | 04.07.25 17:17 von: | woroda |
| Anzahl Beiträge: | 991 | |
| Leser gesamt: | 321337 | |
| davon Heute: | 17 | |
bewertet mit 5 Sternen |
||
|
|
||
Screenshot aus Yahoo Finance
https://finance.yahoo.com/quote/ORMP?p=ORMP&.tsrc=fin-srch
Phase 3 Oral Insulin (ORMD-0801) Trials for the Treatment of Type 2 Diabetes: Over 75% Enrollment Completed
Upcoming Milestones:
6-month topline efficacy results from larger ORA-D-013-1 trial expected in 2022
ORA-D-013-2 trial expected to complete enrollment in 2022
Oravax Medical, Inc.: Oral COVID-19 Vaccine
Upcoming Milestones:
Topline data from Phase 1 expected H1 2022
Initiation of Phase 2/3 oral COVID-19 vaccine trials expected H2 2022
Phase 2 NASH Trial: 50% Enrollment Completed
Upcoming Milestones:
Enrollment completion expected H1 2022
Topline data expected in H2 2022
Oral GLP-1
Upcoming Milestone:
Bioavailability (PK and PD) expected in H1 2022
https://www.oramed.com/oramed-issues-annual-message-to-shareholders/
Oramed’s Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians
– 76 Percent of the Physicians Responded They “Definitely Would” or “Probably Would” Prescribe Oramed’s Oral Insulin Candidate for Type 2 Diabetes Patients
zu #936
Eine KE dürfte auch bald ins Haus stehen.
Date: Wednesday, May 25, 2022
Location: Fontainebleau Miami Beach Hotel, Miami, Florida


